Depression

BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Retrieved on: 
Monday, March 18, 2024
Depression, Deep, Transcranial magnetic stimulation, Brainsway, Prevalence, Veteran, Mental, Memory, Partnership, TMS, Acquisition, Hope, DSM-IV codes, Military personnel, Marketing, Suicide, Nursing

Katie’s Way Plus will now grow to an extensive network of approximately 40 Deep TMS systems.

Key Points: 
  • Katie’s Way Plus will now grow to an extensive network of approximately 40 Deep TMS systems.
  • “We are delighted to continue supporting Katie's Way Plus in its pivotal mission of delivering specialized care to U.S. service members, veterans, and their families,” said Chris Boyer, BrainsWay’s Vice President of Marketing.
  • “The efficacy demonstrated by BrainsWay's advanced Deep TMS technology in the treatment of depression is transformational.
  • In one study conducted across 27 states, it was found that the suicide rate among veterans is 50% higher than non-veterans1.

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, Depression, Washington Convention Center, Government, Development, Veteran, Walter, Patient, Insomnia, Concussion, TBI, Anxiety, MTEC, Chronic pain, Traumatic brain injury, Dementia, PTSD, Medical device

HOUSTON, TEXAS, March 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced it was selected and provided a poster presentation at the “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” on March 12, 2024, which was held at the Walter E. Washington Convention Center in Washington, D.C.

Key Points: 
  • The U.S. Army Medical Research and Development Command’s (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA), with support of MTEC, hosted the State of the Technology meeting focused on non-invasive neuroassessment tools.
  • This was an ideal venue for our poster presentation as the conference attendees included many of the leading thought leaders and decision-makers from both the public and private sectors.
  • Notably, both the DoD and BARDA’s concerns continue to grow surrounding TBI, and we’re seeing the US Government significantly invest in new, non-drug therapeutic options to address TBI in support of struggling warfighters and veterans.
  • We could not have been more pleased with the overwhelming response to our presentation and look forward to providing more details on our latest study in an upcoming abstract publication.”

Special Needs Network Secures Over $1 Million in Grant Funding for Groundbreaking Mental Health Initiative

Retrieved on: 
Tuesday, March 12, 2024
BIPOC, Depression, California Department, Disability, Latinx, Grammatical mood, Autism spectrum, Disability studies, African Americans, Anxiety, Toyota, DHCS, SNN, Spectrum, Nursing

This program aims to address the disparities in autism identification and services, particularly among African American and LatinX students.

Key Points: 
  • This program aims to address the disparities in autism identification and services, particularly among African American and LatinX students.
  • Furthermore, SNN has received a $750,000 grant from the California Department of Health Services (DHCS) as part of the California Youth Behavioral Health (CYBH) initiative, dedicated to supporting mental health initiatives for youth.
  • This funding will bolster SNN's efforts to deliver culturally competent, anti-racist behavioral health services right in the communities that need them ymost.
  • Special Needs Network, Inc. is a nonprofit grassroots 501(c)(3) organization responding to the crisis of autism and other developmental disabilities in underserved communities.

Ancora Issues Letter to Fellow Shareholders Regarding Norfolk Southern’s Failures of Diligence and Poor Judgment in Appointing John Orr as COO

Retrieved on: 
Friday, April 5, 2024
Professional Services, Insurance, Finance, Asset Management, Consulting, Banking, Letter, Exercise, Canadian Pacific Railway, Precision, History, Transport, Disclosure, Surface Transportation Board, KCS, Road, Workplace, Employment, CPKC, Risk, Woman, CSX, Illinois Central Railroad, Safety, CSX Corporation, Depression, Canadian National Railway, EVP, PSR, Meridian Speedway, NSC, Annual general meeting, Weakness, Female, Behavior, Verbal abuse, Security (finance)

Ohio-based Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”), which owns a large equity stake in Norfolk Southern Corporation (NYSE: NSC) (“Norfolk Southern” or the “Company”), today issued the below letter to fellow shareholders regarding the Board of Directors’ (the “Board”) apparent failures of diligence and poor judgment in appointing John Orr as COO.

Key Points: 
  • Ohio-based Ancora Holdings Group, LLC (collectively with its affiliates, “Ancora” or “we”), which owns a large equity stake in Norfolk Southern Corporation (NYSE: NSC) (“Norfolk Southern” or the “Company”), today issued the below letter to fellow shareholders regarding the Board of Directors’ (the “Board”) apparent failures of diligence and poor judgment in appointing John Orr as COO.
  • Ancora is a sizable shareholder of Norfolk Southern, meaning our interests and your interests are squarely aligned.
  • The Board and Mr. Shaw provided CPKC with excessive financial and strategic consideration that weakens Norfolk Southern’s long-term competitive positioning.
  • Norfolk Southern operated from a position of desperation, and shareholders and other stakeholders now stand to pay a steep price.

Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, General Health, Mental Health, Health, Pharmaceutical, Observational study, Depression, Disability, Commercialization, Medication, Patient, Mental health, Research, Biomarker, Doctor of Philosophy, DSM-IV codes, MD, Digital data, Clinical trial, Multimedia, Nursing

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a global pharmaceutical company, announces the launch of My Mental Health Journey , a longitudinal registry study that aims to advance research in depression and mental health.

Key Points: 
  • Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a global pharmaceutical company, announces the launch of My Mental Health Journey , a longitudinal registry study that aims to advance research in depression and mental health.
  • Verily Life Sciences LLC (Verily), a precision health technology company, will recruit participants and run the study.
  • View the full release here: https://www.businesswire.com/news/home/20240404726198/en/
    The My Mental Health Journey registry will enroll U.S.-based adults experiencing symptoms of depression to help Otsuka better understand mental health conditions, such as major depressive disorder, across time and in the real-world setting.
  • Participants in the My Mental Health Journey may receive compensation for study activities, educational resources, updates on future clinical studies, and other opportunities to help advance depression research.

The Hartford And Active Minds Collaborate To Support The Mental Health Of Young Adults

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Philanthropy, Consumer, Mental Health, Fund Raising, Teens, Foundation, Marketing, Insurance, Communications, Human Resources, Other Philanthropy, Health, Depression, Culture, Survival, Education, National Alliance, Public policy, Mental health, Active, NAMI, Hope, Generation Z, Suicide, Mental disorder, Active Minds, Multimedia, Workplace, DSM-IV codes, Gen, Nursing

“Gen Z workers have an urgent need for mental health help that we cannot ignore,” said The Hartford’s Chairman and CEO Christopher Swift. “We hope more business, education, and public policy leaders will join us in a united effort to address today’s mental health crisis. We believe that working together -- with young adults as equal and powerful partners – we can change the culture around mental health, resulting in healthier workplaces and communities for all.”

Key Points: 
  • The Hartford , a leading provider of workers’ compensation and employee benefits, and Active Minds , a leading nonprofit organization dedicated to promoting mental health awareness and providing resources for mental health support, are collaborating to better support the youngest generation in the workplace.
  • We believe that working together -- with young adults as equal and powerful partners – we can change the culture around mental health, resulting in healthier workplaces and communities for all.”
    With a shared focus on prevention and action, The Hartford and Active Minds are providing direct support to young adults and mobilizing the next generation of mental health advocates.
  • Available on the Active Minds’ Cause + Career professional development platform, the new resource covers:
    Signs to know when mental health is needed,
    Types of mental health resources that are typically offered at work, and
    Tips on how to engage in a supportive conversation about mental health.
  • Together with these leaders in the national mental health movement, The Hartford aims to encourage employers to prioritize employee mental health and help millions of Americans enjoy healthier lives.

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

Retrieved on: 
Wednesday, April 3, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Alertness, Depression, EEG, Motivation, ClinicalTrials.gov, MDD, Patient, Neuroscience, Anhedonia, H3, Pleasure, Alto, Cognition, Safety, Pharmacokinetics, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.
  • The present study will evaluate these effects in patients with MDD to determine the potential of ALTO-203 as an antidepressant.
  • “In a Phase 1 study, ALTO-203 demonstrated an acute increase in positive emotion relative to placebo and across several dosage levels.
  • This Phase 2 study consists of two sequential double-blind, placebo-controlled treatment periods and examines two doses of ALTO-203 and placebo given as monotherapy in patients with MDD.

Cathy Nguyen Named Provider of the Month at Relief Mental Health in Chicago

Retrieved on: 
Tuesday, April 2, 2024
Men, Research, General Health, LGBTQ+, Pharmaceutical, Consumer, Mental Health, Science, Neurology, Biotechnology, Women, Seniors, Health, Depression, Mental health, Brain, MDD, Empathy, Patient, Transcranial magnetic stimulation, TMS, Bipolar disorder, Anxiety, OCD, Cathy, Month, DSM-IV codes, Provider, MSN, TRD, Suicidal ideation, Field line, Esketamine, FDA, Nursing

Relief Mental Health , a leading outpatient provider of transcranial magnetic stimulation (TMS), psychedelic therapy, psychiatric medication management, and talk therapy, is thrilled to announce Psychiatric Nurse Practitioner Cathy Nguyen, MSN APRN PMHNP-BC as its esteemed Provider of the Month.

Key Points: 
  • Relief Mental Health , a leading outpatient provider of transcranial magnetic stimulation (TMS), psychedelic therapy, psychiatric medication management, and talk therapy, is thrilled to announce Psychiatric Nurse Practitioner Cathy Nguyen, MSN APRN PMHNP-BC as its esteemed Provider of the Month.
  • Nguyen has exhibited exceptional dedication and expertise in providing innovative mental health care to the community at Relief’s West Loop clinic in Chicago.
  • Susan Mueller, CEO of Relief Mental Health, expressed her admiration for Nguyen’s commitment to the organization’s core values.
  • To make an appointment with Nguyen or for more information about the innovative services offered at Relief Mental Health, call 855.205.4764, email [email protected] or visit reliefmh.com .

Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

Retrieved on: 
Monday, April 1, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Depression, Psychiatry, Brain, Mirai, Medication, MDD, Patient, DSM-IV codes, Therapy, Cognition, Regulation, Otsuka Pharmaceutical, MADRS, Multimedia, Clinical Global Impression, Emotion, Food, Pharmaceutical industry

Unlike wellness apps, the Rejoyn app is a medical device authorized by the FDA for prescription by a healthcare professional.

Key Points: 
  • Unlike wellness apps, the Rejoyn app is a medical device authorized by the FDA for prescription by a healthcare professional.
  • “While traditional approaches are often effective, many are left with only a partial response to treatment.
  • “The clearance of Rejoyn signals a fundamental change in how clinicians can treat symptoms of major depressive disorder.
  • Rejoyn does not monitor the patient’s symptoms or clinical status and cannot send or receive alerts or warnings to the prescriber.

Brightside Health Raises Strategic Series C, Welcomes Trip Hofer to Board of Directors

Retrieved on: 
Tuesday, March 26, 2024
Mental Health, Health, Depression, S32, Growth, Entrepreneurship, Trip, General partnership, Patient, ACME, Publishing, News, Anxiety, DSM-IV codes, MD, Hofer, Blue Cross, Blue Shield, Pharmaceutical industry

Telemental health company Brightside Health today announced a strategic Series C raise led by S32, as well as the appointment of industry titan Trip Hofer to the Board of Directors to advise on go-to-market strategy and execution.

Key Points: 
  • Telemental health company Brightside Health today announced a strategic Series C raise led by S32, as well as the appointment of industry titan Trip Hofer to the Board of Directors to advise on go-to-market strategy and execution.
  • “I’m honored to be joining Brightside Health’s Board of Directors as the company reaches this impressive milestone,” said Trip Hofer, Brightside Health board member and former CEO of Optum Behavioral Health Solutions.
  • In fact, Brightside Health recently announced an expansion with payer partners including CareOregon, Blue Cross and Blue Shield of Texas, and Centene.
  • “We’re thrilled to announce this raise and simultaneously welcome Trip, an incredible industry thought leader, to help propel Brightside Health into the next phase of our growth,” said Brad Kittredge, Co-Founder and CEO of Brightside Health.